The Impact of Vitamin D on Skin Aging

Georgeta Bocheva $^{1,*}$, Radomir M. Slominski $^{2,3}$ and Andrzej T. Slominski $^{2,4,5,*}$

Abstract: The active metabolites of vitamin D$_3$ (D$_3$) and lumisterol (L$_3$) exert a variety of antiaging and photoprotective effects on the skin. These are achieved through immunomodulation and include anti-inflammatory actions, regulation of keratinocytes proliferation, and differentiation programs to build the epidermal barrier necessary for maintaining skin homeostasis. In addition, they induce antioxidative responses, inhibit DNA damage and induce DNA repair mechanisms to attenuate premature skin aging and cancerogenesis. The mechanism of action would involve interaction with multiple nuclear receptors including VDR, AhR, LXR, reverse agonism on ROR$_\alpha$ and $\gamma$, and nongenomic actions through 1,25D$_3$-MARRS receptor and interaction with the nongenomic binding site of the VDR. Therefore, active forms of vitamin D$_3$ including its canonical (1,25(OH)$_2$D$_3$) and noncanonical (CYP11A1-intitated) D$_3$ derivatives as well as L$_3$ derivatives are promising agents for the prevention, attenuation, or treatment of premature skin aging. They could be administrated orally and/or topically. Other forms of parenteral application of vitamin D$_3$ precursor should be considered to avoid its predominant metabolism to 25(OH)D$_3$ that is not recognized by CYP11A1 enzyme. The efficacy of topically applied vitamin D$_3$ and L$_3$ derivatives needs further clinical evaluation in future trials.

Keywords: skin aging; photoaging; skin immune responses; vitamin D; vitamin D metabolites; photoprotection

1. Introduction

Skin, like any other organs, undergoes progressive decline in its physiological, morphological, and functional features during aging [1–4]. The phenomenon of aging is natural and genetically predisposed. The functions of the skin are crucial for the homeostasis and survival. As the largest organ in the human body, the skin, together with the hypodermis (subcutaneous fat), is both the source and the target for several hormones and neuromediators [5–17], making it an independent peripheral endocrine organ [5,18]. The skin has also the capacity of producing the prohormone vitamin D and transforming it to active metabolites [19–25], which can exert several different effects on the main skin cells (keratinocytes and fibroblasts) [20,25–29] and immune cells [4,28,30,31] via the activation of the nuclear vitamin D receptor (VDR) [29,32–35]. Vitamin D plays a pivotal role in skin homeostasis contributing to its barrier function [20,29,36–38]. Moreover, as an essential part of a functioning immune system, active forms of vitamin D modulate the cutaneous immunity [8,30,39].

The gold standard of analyzing a vitamin D status is by measuring its major circulating metabolite, 25-hydroxyvitammin D$_3$ (25(OH)D$_3$), via high-performance liquid chromatography (HPLC) or liquid chromatography tandem–mass spectrometry (LC-MS/MS) [40–42].
Recently, a novel sensitive and specific LC-MS/MS method of the simultaneous measurement of 13 circulating metabolites of vitamin D₃ and D₂ was presented [43].

Importantly, subclinical (30–50 nmol/L) and clinical vitamin D deficiency (<30 nmol/L) in the general population has become a global problem worldwide [44–48]. Several physiological factors may influence vitamin D status, such as age, body mass index (BMI), skin type, pregnancy, and exclusive breastfeeding [49–53]. The genetic polymorphisms of some genes involved in skin pigmentation (TYR, TYRP1, EXOC2, and DCT) are also associated with 25(OH)D₃ serum concentration [54]. Many environmental factors contribute to vitamin D deficiency, such as the winter season, inadequate sun exposure, and high latitude location [55,56]. Sun avoidance and air pollution are the main factors leading to insufficient UVB exposure. Moreover, ozone and particulate matter (PM) can directly affect the cutaneous production of vitamin D [57]. Additionally, air pollutants, persistent organic pollutants, and heavy metals can behave like endocrine-disrupting chemicals (EDCs), which may cause vitamin D deficiency directly or indirectly. The latter would be secondary to a weight gain, the dysregulation of parathyroid hormone and calcium homeostasis, and a thyroid dysfunction [57,58]. Increasing evidence suggests that smoking can also decrease the serum levels of 25(OH)D₃ [57].

With advancing age, the capacity of the skin to produce vitamin D₃ decreases (irrespective of the season), and the degradation of its active forms increases [59,60]. It was found that the concentration of the precursor of vitamin D₃ in the skin, 7-dehydrocholesterol (7-DHC), declines approximately by 50% from age 20 to age 80 years [59]. Several other factors contribute to the vitamin D deficiency state in accelerated age, including limited sun exposure, insufficient dietary intake of vitamin D, or diseases causing malabsorption. The vitamin D deficiency, which is common in advanced age, can decrease the important physiological functions of the skin such as protection from the environment and prevention of cancer development [25,39,61–66].

In this review, we aimed to discuss the significance of vitamin D in the skin aging process.

2. Skin Aging—Your Skin Can Reveal Stories

Skin aging is a complex process that is influenced by the total exposure of both intrinsic and extrinsic factors over the human lifespan (skin exposome), which is responsible for the progressive morphological and functional alterations of the aged skin [1,67–69]. The main internal factors affecting the chronological (physiological) skin aging include a hormonal decline and changes in gene expression with advancing age [1]. In addition, the cutaneous regenerative potential decreases with the age due to the excessive senescence of keratinocytes, fibroblasts, and melanocytes over time, which contributes to skin aging [70–72]. The aged skin is characterized by fine wrinkles and atrophy with reduced elasticity. This chronological aging affects all skin areas but shows phenotypic differences among different anatomical regions, and it varies significantly within different populations [67,73]. The single nucleotide polymorphisms (SNPs) of the MC1R gene (main regulator of melanin pigmentation [74]) are significantly linked to a perceived facial age, providing a new molecular base of youthful looks [75].

The most prominent external stressors affecting skin and causing its premature aging include ultraviolet (UV) radiation [76,77], ambient pollutants [78–82], and smoking [57,83]. The continuous exposure of the skin to these environmental insults stimulates the production of reactive oxygen species (ROS) and generate oxidative stress [84,85]. The environmental factors can also cause an impairment of the epidermal barrier function [69] and alterations in skin microflora [86,87], leading to significant morbidity [2,88].

Ultraviolet radiation (UVR) is the most harmful external factor contributing to the cutaneous photodamage on the sun-exposed areas. Photoaged skin is presented as a dry, deep-wrinkled skin with rough texture, dyschromia and senile lentigines, vascular complications, etc. [68,89]. UVR decreases the expression of filaggrin that contributes to epidermal hydration, so its downregulation from UVR could explain the skin xerosis in photoaging [90]. Both UVA (315–400 nm) and UVB (280–315 nm) have been shown
to contribute to photoaging, either by imbalanced ROS production or by direct DNA damage [83]. However, UVA is considered to play a major role in the aging process. UVA represents more than 80% of total daily UV irradiation and can penetrate 5–10 times deeper into the reticular dermis, where it can damage the extracellular matrix (ECM) more significantly than UVB [91]. Moreover, UVA exposure increases the expression of matrix metalloproteinases (MMPs), especially the expression of the collagenolytic enzyme MMP-1 in dermal fibroblasts, which acts as an important regulator in photoaging [92,93]. Additionally, the chronic UVA irradiation inhibits hyaluronan synthesis, thus altering the composition of proteoglycans in the dermis [94]. A long-term exposure of UVA is related to photoaging and photocancer due to an overproduction of ROS and reactive nitrogen species (RNS), which can disrupt both the nuclear and mitochondrial DNA [95,96]. UVB can penetrate only through the epidermis but is biologically more active. It also induces the transformation of 7-DHC to vitamin D₃ [97,98]. UVB absorbed by DNA and RNA induces a formation of cyclobutane pyrimidine dimers (CPDs) and other photoproducts [99], thus inducing various solar signature mutations in specific genes, including the tumor suppressor gene p53 [100,101]. UV induces an accumulation of p53 protein in the nucleus that in turn activates the transcription of genes responsible for cell cycle arrest allowing DNA repair, as well as causing an induction of apoptosis of the cells with unrepaired DNA damage [102,103]. Specific p53 mutations can be found in high rates, not only in actinic keratosis (precancerous state) and squamous cell carcinomas (60–90%) with typical UV signature, but also in the normal appearance of UV-exposed skin (about 75%), compared with a much lower rate of such mutations in healthy sun-protected skin (5% of all cases) [104].

Chronic sunlight exposure, together with the persistence of cellular senescence, can drive an impaired regenerative capacity of the skin, chronic inflammation, and photoaging, which correlates with enhanced cancer risk [77,105–107]. Thereby, photoaging results in premature skin aging. Although some aging mechanisms share several similarities or overlapping, photoaged skin differs from physiologically aged skin in the ECM changes. Photaged skin is characterized by degraded collagen and accumulated aberrant elastin fibers and glycosaminoglycans, whereas physiologically aged skin is presented by the atrophy of dermal structures [108].

The negative impact of ambient pollutants on human health and the human skin is of growing concern [109]. Ozone (O₃) from the smog and PM, primarily contacting with the skin, is capable to stimulate ROS production and generate oxidative stress, leading to phenotypic features of extrinsic aging [69]. It was found that chronic exposure to PM leads to pigment spots and deep nasolabial folds [110,111]. Moreover, ultrafine particles (<0.1 µm) can penetrate tissues and localize in the mitochondria, causing an aberrant mitochondrial function because of the oxidative processes [112]. Additionally, the photo-pollution exposure may aggravate UVR-mediated skin aging [113].

UVR, predominantly UVA, by the excessive amount of ROS activates the mitogen-activated protein kinases (MAPKs) and transcription factors such as nuclear factor erythroid 2-like (Nrf2), c-Jun-N-terminal kinase (JNK), and nuclear factor-κB (NF-κB), and increases the transcription of MMPs [114]. Activated MMPs, together with the decreased expression of MMP inhibitors (TIMP), cause a dysregulation of the ECM homeostasis and a progressive damage of collagen and elastin [115]. Additionally, UVR impairs the endogenous antioxidant enzymes, leading to an increased oxidative damage of collagen. The destruction of ECM integrity is visualized as wrinkle appearance in photo-damaged skin [93]. The activation of redox-sensitive transcription factors, the activator protein-1 (AP-1) and NF-κB, involved in wrinkle formation and inflammation, plays crucial roles in skin aging [88]. Both factors, NF-κB and AP-1, are elevated within hours after cutaneous exposure to low-dose UVB. The upregulation of AP-1 suppresses the transforming growth factor β (TGF-β) receptors, which further blocks the synthesis of procollagen [116,117]. Additionally, activated AP-1 stimulates the degradation of collagen by MMPs and triggers the main activator of the inflammatory response NF-κB [118]. NF-κB signaling is a
well-known regulator of tissue homeostasis, and its central role in skin aging was recently underlined [119]. The ROS-induced activation of NF-κβ drives an increase of proinflammatory cytokines and MMPs and decreases TGF-β and type I collagen synthesis [119]. The proinflammatory cytokines (interleukin (IL)-1, IL-6, and tumor necrosis factor (TNF)-α) stimulate inflammatory responses and enhance the activation of NF-κβ [95]. It was found that NF-κβ expression could increase in mitochondrial DNA (mtDNA)-depleter mice and after restoring the mitochondrial function, the NF-κβ expression could be reduced. These data confirm that NF-κβ signaling is a key mechanism contributing to the skin and hair follicle pathologies [120]. Due to the longer wavelength, UVA reaches the dermal fibroblasts in vivo with the activation of the Nrf2-mediated expression of antioxidant genes. Unlike UVA, UVB does not activate Nrf2 in skin cells or even appears to have an inhibitory effect [121]. However, vitamin D₃ derivatives, which are products of UVB action, do activate Nrf2 signaling [122]. The endogenous Nrf2 is essential for the protection of skin cells against oxidative insults and for regulating the redox balance during skin aging [123,124]. Many in vitro and in vivo studies confirmed the importance of the transcription factor Nrf2 and its downstream signaling in UV protection [125,126].

Indeed, the human skin aging is mainly driven by oxidative events. An extensive ROS production and insufficient scavenging activity or a mitochondrial dysfunction are crucial events in oxidative stress-induced skin aging. The high levels of ROS lead to oxidative damage of lipids, proteins, genomic, and mtDNA, and also can deplete and damage the antioxidant defense systems of the skin (both non-enzymatic and enzymatic one) [85,127]. Accumulating evidence support a strong link between the mitochondrial dysfunction and the aging process [126]. Many studies demonstrate a decrease in mtDNA content and mitochondrial number during aging. It is thought that mitochondrial dysfunction plays a role in accelerated cellular senescence, seen in advancing age [128–130]. Furthermore, mitochondria are believed to contribute to 90% of generated ROS in the cells [95]. mtDNA, as an important target for ROS, is highly vulnerable to the oxidative damage and possesses inefficient DNA repair mechanisms [96,131]. The functional decline of the mitochondria leads to vicious cycle effect contributing to further enhancement of ROS production [127,132].

3. Effects of Vitamin D₃ on the Skin

3.1. Impact Paths on the Skin

Excessive exposure to solar UVR accelerates skin aging and could trigger cutaneous carcinogenesis [133]. However, UVR plays a beneficial role in the regulation of many skin functions [56,77,134]. The same UVB, responsible for the increase of non-melanoma skin cancer, is required for vitamin D₃ production in the skin that supplies more than 90% of the vitamin D₃ body’s requirement [44,55,135]. In the skin, vitamin D₃ is essential for the formation of the epidermal barrier and hair follicles, and its deficiency has been linked to many proliferative and inflammatory cutaneous disorders [20,29,44,136].

Upon the absorption of UVB, 7-DHC is transformed to vitamin D₃ in the skin, a process accelerated by thermal energy. Prolonged UVB exposure can also generate tachysterol (T₃) and lumisterol (L₃) [24,97]. These reactions are non-enzymatic and dependent on the UVB dose and the temperature. Vitamin D₃ can be activated through canonical and non-canonical pathways with similar activation of L₃ to biologically active metabolites (Figure 1). In the classical pathway, vitamin D₃ is hydroxylated to 25-hydroxyvitamin D₃ (25(OH)D₃) by CYP2R1 and/or CYP27A1 in the liver with further hydroxylation by CYP27B1 in the kidney, skin, and other tissues to its biologically active metabolite 1,25(OH)₂D₃ [20,21,137].

In the alternative (non-canonical) pathway, vitamin D₃ can be activated by CYP11A1 with further modification by other cytochrome enzymes leading to production of large number of metabolites in humans [21,36,138–142] (Figure 1), some of which are non- or low-calcemic at high, therapeutic, doses [143–146]. The major CYP11A1-derived vitamin D₃ products are 20(OH)D₃ and 20,23(OH)₂D₃ [23,139,147,148]. In addition, 20(OH)D₃ can be defined also as a natural product because its presence in the honey [149]. The L₃ can
also be metabolized to biologically active derivatives [150–152], which are not recognized by the 7-DHC reductase [153].

The main genomic effects and biological responses of vitamin D metabolites in the skin are mediated through their binding to the nuclear VDR [32,61,154–156]. Notably, VDR has been reported to regulate about 3% of mammalian genome due to its broad expression in all tissues [4,34,157,158]. The skin also expresses the VDR and serves not only as a source but also as a site for the action of vitamin D$_3$ [28,39]. Additionally, the VDR activated by classical 1,25(OH)$_2$D$_3$ can induce rapid response signaling through a non-genomic, membrane-associated mechanism based on an alternative ligand-binding site [159] or through action on 1,25D$_3$-MARRS receptor [156,160,161]. Similar non-genomic activities for CYP11A1-derived hydroxyderivatives are still not established. SNPs can affect VDR activity favoring a development of melanoma and non-melanoma skin tumors [162,163]. VDR functions as a tumor suppressor [164] and a decrease in its expression is associated with progression of cutaneous melanoma [165,166]. On the opposite, the nuclear VDR expression has been found significantly elevated (moderate to strong) in squamous cell carcinomas (SCCs) and basal cell carcinomas (BCCs) compared to in normal skin [167,168]. Thus, targeting VDR with vitamin D seco steroids (especially low calcemic ones) would be rational in skin cancer prevention, attenuation, or therapy [62,64,169].

**Figure 1.** Noncanonical pathways of vitamin D$_3$ and lumisterol (L$_3$) activation (reprinted from [61] with the permission from Springer). D$_3$, L$_3$, and 7-DHC are substrates for CYP11A1 that produces the corresponding hydroxyderivatives. In the case of L$_3$ and 7-DHC, the side chain can be cleaved by CYP11A1 to produce 7DHP or pL that can be further metabolized by steroidogenic enzymes (ES). In the skin, UVB acting on 5,7-dienes can lead to the production of D$_3$, L$_3$, and T$_3$ derivatives with a full-length side chain and pD, pL, and pT derivatives with a shortened side chain. While the cut-off for UVC/UVB is 280 nm, we show the range of 290–315 nm because wavelengths below 290 nm are filtered by the ozone layer and no additional pre-D$_3$ is produced above 315 nm [170]. 7DHC, 7-dehydrocholesterol; 7DHP, 7-dehydropregnenolone; pD, pregnanacalciferol; pL, preganalumisterol; D$_3$, vitamin D$_3$; L$_3$, lumisterol; T$_3$, tachysterol; OH, hydroxyl group; number before OH, carbon number with OH; number in subscripts after (OH), number of hydroxyl groups.
CYP11A1-derived hydroxyderivatives can regulate some skin functions through other nuclear receptor such as retinoic acid-related orphan receptors (ROR) α and γ, which expressed in the skin [171]. The endogenously produced nonclassical vitamin D₃ hydroxyderivatives, 20(OH)D₃ and 20,23(OH)₂D₃ can act as weak RORα and RORγ inverse agonists [155,171,172]. Moreover, these hydroxyderivatives could exert anti-inflammatory effect and could inhibit tumor progression in the skin via RORγ-mediated mechanism [173].

Alternatively, the classical 1,25(OH)₂D₃ and CYP11A1-initiated vitamin D₃ derivatives can act as agonists on aryl hydrocarbon receptor (AhR) [174] and liver X receptors (LXR) [175]. Moreover, the activation of AhR is the top canonical pathway for 20,23(OH)₂D₃ [174]. This receptor regulates cellular proliferation, inflammation, and melanogenesis in the skin [176]. Although many different ligands can target AhR, some functional studies and molecular modeling can predict that secosteroidal signal transduction further leads to the downregulation of proinflammatory responses [177], detoxification, and antioxidative action [61,174].

Summarizing, the biologically active classical and novel vitamin D₃ metabolites exert different affinities to multiple receptors in the skin and through their modulation they can influence different cutaneous pathologies. In addition to act on the VDR, the active forms of vitamin D can act on alternative nuclear receptors including RORs, AhR, LXR, and 1,25D₃-MARRS receptor. The active forms of vitamin D₃ have various functions, which partially overlap in their anti-inflammatory, antimicrobial, antiproliferative, prodifferentiation, antifibrotic, and antioxidative effects on the skin [20,36,63,141,145,178]. Along with the best characterized 1,25(OH)₂D₃, CYP11A1-derived products of vitamin D₃ and L₃ exhibit photoprotective properties against UVR-induced skin damage (Figure 2) [37,61,179–183].

Figure 2. Photoprotective effects of vitamin D₃ in premature skin aging and cutaneous cancerogenesis. Abbreviations: 7-DHC, 7-dehydrocholesterol; AK, actinic keratosis; BCC, basal cell carcinoma; SCC, squamous cell carcinoma; MM, malignant melanoma.
3.2. Effects on the Cutaneous Immune Function

Vitamin D₃ and its analogues and precursors play an important complex role in the regulation of both the innate and adaptive immune systems, including in the skin [8,184,185]. There is a clear connection between vitamin D deficiency and incidences of infections and immune-mediated skin diseases [31,186–188]. The expression of the VDR has been found in almost all immune cells including T- and B-lymphocytes (Lym), macrophages, mast cells, natural killer (NK) cells, and regulatory T cells (Tregs), but it is differently regulated [189]. Monocytes, for example, lose VDR expression levels during differentiation towards macrophages and dendritic cells (DCs) [190,191]. Immunomodulatory actions of active vitamin D₃ metabolites include the induction of Tregs [192] and Thelper-2 (Th2)-Lym, together with the downregulation of proinflammatory Th1/Th17/Th9-Lym [193]. 1,25(OH)₂D₃ can have both direct and indirect effects on T-Lym [194]. The indirect effect is based on DC-derived cytokines, which modulate Th-Lym response [30]. Directly, 1,25(OH)₂D₃ can suppress the immune cell production of inflammatory cytokines such as interferon gamma (IFN-γ), TNF-α, and IL-2 (Th1 cytokines), IL-17/21 (Th17 cytokines), and Th9 cytokines [193,195,196], while it enhances either the levels of anti-inflammatory IL-10 from Tregs [197] or Th2-derived IL-4 [198]. As a result, vitamin D shifts Th1 inflammatory response towards more tolerogenic Th2 response with an increase of CD4 + CD25 + Tregs reflected to a change in cytokine profile in the skin [199]. Additionally, 1,25(OH)₂D₃ directly regulates antimicrobial peptide (AMP) gene expression in innate immune cells [204,205]. Moreover, it has been found that vitamin D is able to induce essential for antimicrobial defense, production of cathelicidin (LL37) [204] and to modulate the phagocytic activity of macrophages and NK cells [193].

CYP11A1 is expressed also in immune cells [207], where vitamin D can be further metabolized to biologically active hydroxyderivatives [31,39]. Via the activation of VDR or through the inhibition of RORγ-mediated activation, 20(OH)D₃ and 20,23(OH)₂D₃, like 1,25(OH)₂D₃, can attenuate Th17 differentiation, as well as the formation and activity of inflammatory cytokine IL-17 by immune cells [155,208,209]. Thus, Th17-related cutaneous inflammation could be successfully modulated via RORγ inverse agonists such as CYP11A1-derived D₃-hydroxyderivatives, causing the regulation of the immune system and a resistance against autoimmunity [210,211]. The most recently inhibition of collagen-induced autoimmune arthritis by CYP11A1-derived 20(OH)D₃ was reported [212].

3.3. Impact on Skin Aging

The normal vitamin D₃ status is important for a general prevention of premature aging maintaining a healthful skin aging [213,214]. Vitamin D₃ metabolites including its classical (1,25(OH)₂D₃) and novel (CYP11A1-initiated) D₃ hydroxyderivatives exert many beneficial protective effects on the skin, which could influence the process of premature aging via many different mechanisms, leading to a delay or attenuation of both chronological skin aging and photoaging. Skin-resident cells (keratinocytes, fibroblasts, and sebocytes) are capable of locally activating vitamin D₃ [23,36,213] and exhibiting a diverse biological effect such as photoprotection and immunosuppression, similar to the UVR-induced one [179,216].

The process of chronological aging is associated with immunological alteration and the imbalance between inflammatory and anti-inflammatory mechanisms, leading to a chronic low-grade inflammation, known as “inflammaging” state [217,218]. The “inflammaging” phenotype of the skin and hair follicles is a result of both chronic antigen stimulation and continued exposure to oxidative stress caused by ROS and RNS [219,220]. With advancing
age, skin is affected by the profound remodeling of the immune system, leading to a decline in its adaptive capacity [221,222]. Th1- and Th17-related markers, together with the number of epidermal DCs are increased as a function of age [223–225]. DCs during aging appear to be functionally impaired, which contributes to an initiation of inflammatory and autoimmune skin disorders and a loss of their protective role against cutaneous infections. The active forms of vitamin D$_3$ are able to decrease the proliferation and cytotoxicity of T-Lym, as well as to suppress the differentiation of B-Lym and the maturation of DCs [193]. Therefore, vitamin D$_3$ hydroxyderivatives exert potent anti-inflammatory activities including the inhibition of TNF-$\alpha$, INF-$\gamma$, and IL-1/6/9/17 production [4,38,185], suggesting their implication in the modulation of skin inflammation. Moreover, the noncalcemic and nontoxic 20(OH)D$_3$ has shown a similar anti-inflammatory property in vivo to 1,25(OH)$_2$D$_3$ (hypercalcemic in high doses) through the suppression of the immune responses by T- and B-lym [155,212].

Active vitamin D$_3$ metabolites can protect skin against the hazardous effects of skin aging-triggering agents, including UVR, pollution, and microbial infections [179,226–230]. It has been shown that the oral administration of high-dose vitamin D$_3$ shortly after UVB exposure could reverse rapidly the photo-induced cutaneous damage by decreasing the inflammation and induction of the repair mechanisms of the epidermal barrier [38]. There is strong experimental evidence that active vitamin D$_3$ and L$_3$ hydroxyderivatives can induce, in a dose-dependent manner, antioxidative responses and reverse the UVB-mediated ROS production in keratinocytes by the activation of Nrf2 that works for cytoprotection and detoxification, thus attenuating photoaging [122]. Therefore, they serve as protective agents against UVB-induced oxidative stress in cells, pre-treated with each of these active metabolites for 24 h prior to UVB irradiation (50 mJ/cm$^2$) [122]. These hydroxyderivatives stimulate the expression of antioxidant-response genes downstream of Nrf2 (GR, HO-1, CAT, SOD-1, and SOD-2) as well as the expression of HO-1, CAT, and MnSOD at the protein level [122]. The transcription factor Nrf2 plays an important role in the detection of excessive ROS and RNS and in the induction of mechanisms counteracting the oxidative damage and skin pigmentation produced by UVA [121,125,231].

Chronic UVR irradiation, mainly UVB [232] and UVA [233], induces DNA damage and the formation of CPDs that potentially lead to premature skin aging and carcinogenesis. CYP11A1-derived D$_3$ and L$_3$ hydroxyderivatives, along with 1,25(OH)$_2$D$_3$, demonstrate photoprotective and reparative properties by increasing the expression and phosphorylation of p53 with its translocation to the nucleus [61,229,234,235]. The P53 gene family, in particular its isoform p63, might be an important molecular target for vitamin D action in premature aging and cancer [236], which are promoted by similar mechanisms [237].

Moreover, 1,25(OH)$_2$D$_3$ and 1,25(OH)$_2$L$_3$ inhibit DNA damage and facilitate DNA repair by the reduction of CPDs [182,235,238,239] and RNS [178,234]. The photoprotection by 20(OH)D$_3$ and 20,23(OH)$_2$D$_3$ is comparable to 1,25(OH)$_2$D$_3$ reduction of UVB-induced CPDs and DNA fragmentation in vivo [181,182] and in vitro [178]. In addition, both 20(OH)D$_3$ and 20,23(OH)$_2$D$_3$ stimulate differentiation, inhibit proliferation and downregulate proinflammatory responses in keratinocytes via the decrease of NF$\kappa$B activity [240,241]. It was shown recently that not only the pretreatment, but also the post-treatment of keratinocytes with CYP11A1-derived D$_3$ and L$_3$ derivatives can reverse their UVB-induced damage [37,230].

Additionally, 1,25(OH)$_2$D$_3$ can induce rapid and dose-dependent reduction in skin cell apoptosis, and it can increase CPDs repair and decrease the oxidative DNA damage through non-genomic energy-conserving autophagy and mitophagy [227], thus contributing to the intrinsic skin photoprotection mechanism [242].

4. Conclusions and Future Perspectives

Vitamin D$_3$ and its active metabolites exert a variety of antiaging and (photo) protective effects on the skin. These are achieved through immunomodulation that include anti-inflammatory actions and regulation of keratinocytes proliferation and differentiation.
program to build the epidermal barrier necessary to maintain skin homeostasis. In addition, they induce antioxidative responses, inhibit DNA damage and induce DNA repair mechanisms to attenuate premature skin aging and cancerogenesis. Similar actions can be assigned to lumisterol metabolites. Therefore, active forms of vitamin D\textsubscript{3} including its canonical (1,25(OH)\textsubscript{2}D\textsubscript{3}) and noncanonical (CYP11A1-initiated) D\textsubscript{3}-hydroxyderivatives as well as L\textsubscript{3}-derivatives are promising agents for the prevention, attenuation, or treatment of premature skin aging, when applied topically. It is expected that they will attenuate photoaging and perhaps repair the existing damage induced by external stressors. The mechanism of action would involve interaction with nuclear receptors including VDR, AhR, LXR, reverse agonism on ROR\textsubscript{α} and ROR\textsubscript{γ}, and nongenomic actions through 1,25D\textsubscript{3}-MARRS receptor and interaction with the nongenomic binding site of the VDR. The regulatory mechanism affected by D\textsubscript{3} and L\textsubscript{3} derivatives would include the activation of Nrf2 and p53 and the downregulation of NFκβ signaling pathways or the regulation of mitochondrial functions. To prevent skin aging, vitamin D\textsubscript{3} and lumisterol or their derivatives could be administrated orally and/or topically. Other forms of parental application of the vitamin D\textsubscript{3} precursor should be considered to avoid channeling its metabolism to 25(OH)D\textsubscript{3}, which is not recognized by CYP11A1 enzyme [243]. The efficacy of topically applied vitamin D\textsubscript{3} and L\textsubscript{3} derivatives needs further clinical evaluation in future trials.

**Funding:** We acknowledge the support of NIH grants (1R01AR073004 and R01AR071189), a VA merit grant 1I01BX004293 to A.T.S., a grant R21 AI152047 to A.T.S. and C.R., and a grant R21 MD015319 to C.R.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Acknowledgments:** We thank Carlton Philips and Craig Elmets from the department of dermatology, UAB, for the pictures of BCC and SCC.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Bocheva, G.; Slominski, R.M.; Slominski, A.T. Neuroendocrine Aspects of Skin Aging. *Int. J. Mol. Sci.* 2019, 20, 2798. [CrossRef] [PubMed]

2. Bocheva, G.S.; Slominski, R.M.; Slominski, A.T. Immunological Aspects of Skin Aging in Atopic Dermatitis. *Int. J. Mol. Sci.* 2021, 22, 5729. [CrossRef]

3. Zouboulis, C.C.; Adjaye, J.; Akamatsu, H.; Moe-Behrens, G.; Niemann, C. Human skin stem cells and the ageing process. *Exp. Gerontol.* 2008, 43, 986–997. [CrossRef]

4. Reichrath, J.; Zouboulis, C.C.; Vogt, T.; Holick, M.F. Targeting the vitamin D endocrine system (VDES) for the management of inflammatory and malignant skin diseases: An historical view and outlook. *Rev. Endocr. Metab. Disord.* 2016, 17, 405–417. [CrossRef]

5. Slominski, A.; Wortsman, J. Neuroendocrinology of the skin. *Endocr. Rev.* 2000, 21, 457–487. [CrossRef] [PubMed]

6. Slominski, A.T.; Zmijewski, M.A.; Skobowiat, C.; Zbytek, B.; Slominski, R.M.; Steketee, J.D. Sensing the environment: Regulation of local and global homeostasis by the skin’s neuroendocrine system. *Adv. Anat. Embryol. Cell Biol.* 2012, 212, 1–115.

7. Slominski, A.T.; Zmijewski, M.A.; Zbytek, B.; Tobin, D.J.; Theoharides, T.C.; Rivier, J. Key role of CRF in the skin stress response system. *Endocr. Rev.* 2013, 34, 827–884. [CrossRef] [PubMed]

8. Slominski, A.; Zbytek, B.; Nikolakis, G.; Manna, P.R.; Skobowiat, C.; Zmijewski, M.; Li, W.; Janjetovic, Z.; Postlethwaite, A.; Zouboulis, C.C.; et al. Steroidogenesis in the skin: Implications for local immune functions. *J. Steroid Biochem. Mol. Biol.* 2013, 137, 107–123. [CrossRef] [PubMed]

9. Slominski, A.; Wortsman, J.; Tuckey, R.C.; Paus, R. Differential expression of HPA axis homolog in the skin. *Mol. Cell. Endocrinol.* 2007, 265–266, 143–149. [CrossRef] [PubMed]

10. Slominski, A.; Ermak, G.; Hwang, J.; Chakraborty, A.; Mazurkiewicz, J.E.; Mihm, M. Proopiomelanocortin, corticotropin releasing hormone and corticotropin releasing hormone receptor genes are expressed in human skin. *FEBS Lett.* 1995, 374, 113–116. [CrossRef]

11. Slominski, A.; Wortsman, J.; Pisarchik, A.; Zbytek, B.; Linton, E.A.; Mazurkiewicz, J.E.; Wei, E.T. Cutaneous expression of corticotropin-releasing hormone (CRH), urocrin, and CRH receptors. *FASEB J.* 2001, 15, 1678–1693. [CrossRef] [PubMed]
12. Slominski, A.; Szczesniewski, A.; Wortsman, J. Liquid chromatography-mass spectrometry detection of corticotropin-releasing hormone and proopiomelanocortin-derived peptides in human skin. *J. Clin. Endocrinol. Metab.* 2000, 85, 3582–3588. [CrossRef] [PubMed]

13. Ito, N.; Ito, T.; Betterman, A.; Paus, R. The human hair bulb is a source and target of CRH. *J. Investig. Dermatol.* 2004, 122, 235–237. [CrossRef] [PubMed]

14. Slominski, A.; Wortsman, J.; Luger, T.; Paus, R.; Solomon, S. Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress. *Physiol. Rev.* 2000, 80, 979–1020. [CrossRef] [PubMed]

15. Kono, M.; Nagata, H.; Umemura, S.; Kawana, S.; Osamura, R.Y. In situ expression of corticotropin-releasing hormone (CRH) and proopiomelanocortin (POMC) genes in human skin. *FASEB J.* 2001, 15, 2297–2299. [CrossRef]

16. Slominski, A.; Wortsman, J.; Tobin, D.J. The cutaneous serotoninergic/melatoninergic system: Securing a place under the sun. *FASEB J.* 2005, 19, 176–194. [CrossRef]

17. Slominski, A.; Pisarchik, A.; Semak, I.; Sweatman, T.; Wortsman, J.; Szczesniewski, A.; Slugocki, G.; McNulty, J.; Kauser, S.; Tobin, D.J.; et al. Serotoninergic and melatoninergic systems are fully expressed in human skin. *FASEB J.* 2002, 16, 896–898. [CrossRef] [PubMed]

18. Zouboulis, C.C. Human skin: An independent peripheral endocrine organ. *Horm. Res.* 2000, 54, 230–242. [CrossRef]

19. Reichrath, J.; Lehmann, B.; Carlberg, C.; Varani, J.; Zouboulis, C.C. Vitamins as hormones. *Horm. Metab. Res.* 2007, 39, 71–84. [CrossRef]

20. Bikle, D.D. Vitamin D: Newer Concepts of Its Metabolism and Function at the Basic and Clinical Level. *J. Endocr. Soc.* 2020, 4, bvz038. [CrossRef]

21. Tuckey, R.C.; Cheng, C.Y.S.; Slominski, A.T. The serum vitamin D metabolome: What we know and what is still to discover. *J. Steroid Biochem. Mol. Biol.* 2019, 186, 4–21. [CrossRef]

22. Slominski, A.; Kim, T.K.; Zmijewski, M.A.; Janjetovic, Z.; Li, W.; Chen, J.; Kusniatsova, E.; Semak, I.; Postlethwaite, A.; Miller, D.D.; et al. Novel vitamin D photoproducts and their precursors in the skin. *Dermatoendocrinology* 2013, 5, 7–19. [CrossRef]

23. Slominski, A.T.; Kim, T.K.; Li, W.; Tuckey, R.C. Classical and non-classical metabolic transformation of vitamin D in dermal fibroblasts. *Exp. Dermatol.* 2016, 25, 231–232. [CrossRef] [PubMed]

24. Holick, M.F. Vitamin D: A millenium perspective. *J. Cell Biochem.* 2003, 88, 296–307. [CrossRef] [PubMed]

25. Reichrath, J.; Saternus, R.; Vogt, T. Endocrine actions of vitamin D in skin: Relevance for photocarcinogenesis of non-melanoma skin cancer, and beyond. *Mol. Cell Endocrinol.* 2017, 453, 96–102. [CrossRef] [PubMed]

26. Bikle, D.D. Vitamin D and the skin. *J. Bone Miner. Metab.* 2010, 28, 117–130. [CrossRef]

27. Luderer, H.F.; Demay, M.B. The vitamin D receptor, the skin and stem cells. *J. Steroid Biochem. Mol. Biol.* 2010, 121, 314–316. [CrossRef] [PubMed]

28. Bikle, D.D. Vitamin D and the skin: Physiology and pathophysiology. *Rev. Endocr. Metab. Disord.* 2012, 13, 3–19. [CrossRef]

29. Oda, Y.; Hu, L.; Nguyen, T.; Fong, C.; Zhang, J.; Guo, P.; Bikle, D.D. Vitamin D Receptor Is Required for Proliferation, Migration, and Differentiation of Epidermal Stem Cells and Progeny during Cutaneous Wound Repair. *J. Investig. Dermatol.* 2018, 138, 2423–2431. [CrossRef] [PubMed]

30. Martens, P.J.; Gyssemans, C.; Verstuyf, A.; Mathieu, A.C. Vitamin D’s Effect on Immune Function. *Nutrients* 2020, 12, 1248. [CrossRef]

31. Hewison, M. Vitamin D and immune function: An overview. *Proc. Nutr. Soc.* 2012, 71, 50–61. [CrossRef]

32. Lin, Z.; Chen, H.; Belorusova, A.Y.; Bollinger, J.C.; Tang, E.K.Y.; Janjetovic, Z.; Kim, T.K.; Wu, Z.; Miller, D.D.; Slominski, A.T.; et al. 1α,25-Dihydroxyvitamin D3 Interacts with Vitamin D Receptor: Crystal Structure and Route of Chemical Synthesis. *Sci. Rep.* 2017, 7, 10193. [CrossRef]

33. Pike, J.W.; Meyer, M.B.; Bishop, K.A. Regulation of target gene expression by the vitamin D receptor—An update on mechanisms. *Rev. Endocr. Metab. Disord.* 2012, 13, 45–55. [CrossRef]

34. Bouillon, R.; Marcocci, C.; Carmeliet, G.; Bikle, D.; White, J.H.; Dawson-Hughes, B.; Lips, P.; Munns, C.E.; Lazaretti-Castro, M.; Giustina, A.; et al. Skeletal and Extraskelatal Actions of Vitamin D: Current Evidence and Outstanding Questions. *Endocr. Rev.* 2018, 40, 1109–1151. [CrossRef]

35. Bikle, D.D. The vitamin D receptor: A tumor suppressor in skin. *Adv. Exp. Med. Biol.* 2014, 810, 282–302. [CrossRef]

36. Slominski, A.T.; Kim, T.K.; Li, W.; Yi, A.K.; Postlethwaite, A.; Tuckey, R.C. The role of CYP11A1 in the production of vitamin D metabolites and their role in the regulation of epidermal functions. *J. Steroid Biochem. Mol. Biol.* 2014, 144PA, 28–39. [CrossRef] [PubMed]

37. Chaiprasongsuk, A.; Janjetovic, Z.; Kim, T.K.; Schwartz, C.J.; Tuckey, R.C.; Tang, E.K.Y.; Raman, C.; Panich, U.; Slominski, A.T. Hydroxylumisterols, Photoproducts of Pre-Vitamin D3, Protect Human Keratinocytes against UVB-Induced Damage. *Int. J. Mol. Sci.* 2020, 21, 9374. [CrossRef]

38. Scott, J.F.; Das, L.M.; Ahsanuddin, S.; Qiu, Y.; Binko, A.M.; Traylor, Z.P.; Debanne, S.M.; Cooper, K.D.; Boxer, R.; Lu, K.Q. Oral Vitamin D Rapidly Attenuates Inflammation from Sunburn: An Interventional Study. *J. Investig. Dermatol.* 2017, 137, 2078–2086. [CrossRef] [PubMed]

39. Bikle, D.; Christakos, S. New aspects of vitamin D metabolism and action—Addressing the skin as source and target. *Nat. Rev. Endocrinol.* 2020, 16, 234–252. [CrossRef] [PubMed]
40. Binkley, N.; Dawson-Hughes, B.; Durazo-Arvizu, R.; Thamm, M.; Tian, L.; Merkel, J.M.; Jones, J.C.; Carter, G.D.; Sempos, C.T. Vitamin D measurement standardization: The way out of the chaos. J. Steroid Biochem. Mol. Biol. 2017, 173, 117–121. [CrossRef][PubMed]

41. Schöttker, B.; Jansen, E.H.; Haug, U.; Schomburg, L.; Köhrle, J.; Brenner, H. Standardization of misleading immunoassay based 25-hydroxyvitamin D levels with liquid chromatography tandem-mass spectrometry in a large cohort study. PLoS ONE 2012, 7, e48774. [CrossRef]

42. Jenkinson, C. The vitamin D metabolome: An update on analysis and function. Cell Biochem. Funct. 2019, 37, 408–423. [CrossRef]

43. Jenkinson, C.; Desai, R.; Slominski, A.T.; Tuckey, R.C.; Hewison, M.; Handelsman, D.J. Simultaneous measurement of 13 circulating vitamin D3 and D2 mono and dihydroxy metabolites using liquid chromatography mass spectrometry. Clin. Chem. Lab. Med. 2021. [CrossRef]

44. Holick, M.F. Vitamin D deficiency. N. Engl. J. Med. 2007, 357, 266–281. [CrossRef]

45. Palacios, C.; Gonzalez, L. Is vitamin D deficiency a major global public health problem? J. Steroid Biochem. Mol. Biol. 2014, 144, 138–145. [CrossRef][PubMed]

46. Slominski, A.T.; Boźnya, A.A.; Zmijewski, M.A.; Janjetovic, Z.; Kim, T.K.; Grese, L.N.; Riney, S.J.; Nguyen, M.N.; Tuckey, R.C. Novel vitamin D hydroxyderivatives inhibit melanoma growth and show differential effects on normal melanocytes. Cell Biochem. Biophys. 2020, 78, 165–180. [CrossRef][PubMed]

47. Borissova, A.M.; Shinkov, A.; Vlahov, J.; Dakovska, L.; Svinarov, D.; Qayyum, A.M.; Guroji, P.; et al. The Role of Classical and Novel Forms of Vitamin D in the Pathogenesis and Progression of Nonmelanoma Skin Cancers. Adv. Exp. Med. Biol. 2020, 1268, 257–283. [CrossRef]

48. Holick, M.F. The vitamin D deficiency pandemic: Approaches for diagnosis, treatment and prevention. Rev. Endocr. Metab. Disord. 2017, 18, 153–165. [CrossRef][PubMed]

49. Serdar, M.A.; Batu Can, B.; Kilercik, M.; Durer, Z.A.; Aksungar, F.B.; Serteser, M.; Coskun, A.; Ozpinar, A.; Unsal, I. Analysis of Changes in Parathyroid Hormone and 25 (OH) Vitamin D Levels with Respect to Age, Gender and Season: A Data Mining Study. J. Med. Biochem. 2017, 36, 73–83. [CrossRef][PubMed]

50. Shinkov, A.; Borissova, A.M.; Dakovska, L.; Vlahov, J.; Svinarov, D.; Cassabova, L. Winter 25-hydroxvitamin D levels in young urban adults are affected by smoking, body mass index and educational level. Eur. J. Clin. Nutr. 2015, 69, 355–360. [CrossRef][PubMed]

51. Holick, M.F. Bioavailability of vitamin D and its metabolites in black and white adults. N. Engl. J. Med. 2013, 369, 2047–2048. [CrossRef]

52. Kiely, M.; Hemmingway, A.; O’Callaghan, K.M. Vitamin D in pregnancy: Current perspectives and future directions. Ther. Adv. Musculoskelet. Dis. 2017, 9, 145–154. [CrossRef]

53. Lagunova, Z.; Porojnicu, A.C.; Lindberg, F.; Hexeberg, S.; Moan, J. The dependency of vitamin D status on body mass index, gender, age and season. Anticancer Res. 2009, 29, 3713–3720. [CrossRef][PubMed]

54. Rossberg, W.; Saternus, R.; Wagenpeil, S.; Kleber, M.; März, W.; Reichrath, S.; Vogt, T.; Reichrath, J. Human Pigmentation, Cutaneous Vitamin D Synthesis and Evolution: Variants of Genes (SNPs) Involved in Skin Pigmentation Are Associated with 25(OH)D Serum Concentration. Anticancer Res. 2016, 36, 1429–1437. [PubMed]

55. Wacker, M.; Feldt-Rasmussen, U.; Main, K.M. Thyroid effects of endocrine disrupting chemicals. Adv. Exp. Med. Biol. 2021, 18, 266–281. [CrossRef][PubMed]

56. Grant, W.B.; Bhattoa, H.P.; Boucher, B.J. Seasonal variations of U.S. mortality rates: Roles of solar ultraviolet-B doses, vitamin D, gene expression, and infections. J. Steroid Biochem. Mol. Biol. 2017, 173, 5–12. [CrossRef][PubMed]

57. Mousavi, S.E.; Amini, H.; Heydarpour, P.; Amini Chermahini, F.; Godderis, L. Air pollution, environmental chemicals, and smoking may trigger vitamin D deficiency: Evidence and potential mechanisms. Environ. Int. 2017, 105, 133–142. [PubMed]

58. Boas, M.; Feldt-Rasmussen, U.; Main, K.M. Thyroid effects of endocrine disrupting chemicals. Mol. Cell. Endocrinol. 2012, 355, 240–248. [CrossRef][PubMed]

59. MacLaughlin, J.; Holick, M.F. Sunlight and Vitamin D: A global perspective for health. Dermatoendocrinology 2013, 5, 51–108. [CrossRef][PubMed]

60. Grant, W.B.; Bhattoa, H.P.; Boucher, B.J. Seasonal variations of U.S. mortality rates: Roles of solar ultraviolet-B doses, vitamin D, gene expression, and infections. J. Steroid Biochem. Mol. Biol. 2017, 173, 5–12. [CrossRef][PubMed]

61. Slominski, A.T.; Chaiprasongsuk, A.; Janjetovic, Z.; Kim, T.K.; Stefan, J.; Slominski, R.M.; Hanumanthu, V.S.; Raman, C.; Qayyum, A.M.; Guroji, P.; et al. The Role of Classical and Novel Forms of Vitamin D in the Pathogenesis and Progression of Nonmelanoma Skin Cancers. Adv. Exp. Med. Biol. 2020, 1268, 257–283. [CrossRef]

62. Slominski, A.T.; Broźyna, A.A.; Zmijewski, M.A.; Janjetovic, Z.; Kim, T.K.; Rios, V.; Mason, R.S.; Jetten, A.M.; Guroji, P.; et al. The Role of Classical and Novel Forms of Vitamin D in the Pathogenesis and Progression of Nonmelanoma Skin Cancers. Adv. Exp. Med. Biol. 2020, 1268, 257–283. [CrossRef]

63. Tongkao-On, W.; Gordon-Thomson, C.; Dixon, K.M.; Song, E.J.; Liu, T.; Carter, S.E.; Sequeira, V.B.; Reeve, V.E.; Mason, R.S. Novel vitamin D compounds and skin cancer prevention. Dermatoendocrinology 2013, 5, 20–33. [CrossRef][PubMed]
98. Holick, M.F.; Clark, M.B. The photobiogenesis and metabolism of vitamin D. *Fed. Proc.* 1978, 37, 2567–2574.

99. Setlow, R.B.; Carrier, W.L. Pyrimidine dimers in ultraviolet-irradiated DNA’s. *J. Mol. Biol.* 1966, 17, 237–254. [CrossRef]

100. Hussein, M.R. Ultraviolet radiation and skin cancer: Molecular mechanisms. *J. Cutan. Pathol.* 2005, 32, 191–205. [CrossRef]

101. Brash, D.E. UV signature mutations. *Photochem. Photobiol.* 2015, 91, 15–26. [CrossRef]

102. Decraene, D.; Agostinis, P.; Pupe, A.; de Haes, P.; Garmyn, M. Acute response of human skin to solar radiation: Regulation and function of the p53 protein. *J. Invest. Dermatol. B* 2001, 63, 78–83. [CrossRef]

103. Ouhtit, A.; Muller, H.K.; Davis, D.W.; Ullrich, S.E.; McConkey, D.; Ananthaswamy, H.N. Temporal events in skin injury and the early adaptive responses in ultraviolet-irradiated mouse skin. *Am. J. Pathol.* 2000, 156, 201–207. [CrossRef]

104. Nakazawa, H.; English, D.; Randell, P.L.; Nakazawa, K.; Martel, N.; Armstrong, B.K.; Yamashiki, H. UV and skin cancer: Specific p53 gene mutation in normal skin as a biologically relevant exposure measurement. *Proc. Natl. Acad. Sci. USA* 1994, 91, 360–364. [CrossRef]

105. Scharffetter-Kochanek, K.; Brenneisen, P.; Wenk, J.; Herrmann, G.; Ma, W.; Kuhr, L.; Meewes, C.; Wlaschek, M. Photoaging of the skin: A molecular perspective. *J. Investig. Dermatol.* 2002, 128, 2822–2322. [CrossRef]

106. Decraene, D.; Agostinis, P.; Pupe, A.; de Haes, P.; Garmyn, M. Acute response of human skin to solar radiation: Regulation and function of the p53 protein. *J. Invest. Dermatol. B* 2001, 63, 78–83. [CrossRef]

107. Reichrath, J.; Rass, K. Ultraviolet damage, DNA repair and vitamin D in nonmelanoma skin cancer and in malignant melanoma: An update. *Adv. Exp. Med. Biol.* 2014, 810, 208–233. [CrossRef]

108. Quan, T.; He, T.; Kang, S.; Voorhees, J.J.; Fisher, G.J. Solar ultraviolet irradiation reduces collagen in photoaged human skin by blocking transforming growth factor-beta type II receptor/Smad signaling. *J. Biomed. Sci.* 2016, 23, 2684–2696. [CrossRef] [PubMed]

109. Chen, J.H.; Kang, S.; Varani, J.; Lin, J.; Fisher, G.J.; Voorhees, J.J. Decreased extracellular-signal-regulated kinase and increased stress-activated MAP kinase activities in aged human skin in vivo. *J. Invest. Dermatol.* 2000, 115, 177–182. [CrossRef] [PubMed]

110. Christensen, L.; Suggs, A.; Baron, E. Ultraviolet photobiology in dermatology. *Adv. Exp. Med. Biol.* 2017, 996, 89–104. [CrossRef]

111. Quan, C.; Cho, M.K.; Perry, D.; Quan, T. Age-associated reduction of cell spreading induces mitochondrial DNA common deletion mutation in p53 gene-deficient mice. *Exp. Dermatol.* 2011, 20, 606–612. [CrossRef]

112. Schäfer, M.; Werner, S. Nrfr2—A regulator of keratinocyte redox signaling. *Free Radic. Biol. Med.* 2015, 88, 243–252. [CrossRef]

113. Chaiprasongsuk, A.; Janietovic, Z.; Kim, T.K.; Jarrett, S.G.; D’Orazio, J.A.; Holick, M.F.; Tang, E.K.Y.; Tuckey, R.C.; Panich, U.; Li, W.; et al. Protective effects of vitamin D and gut microflora against UVB-induced damage in human keratinocytes involve activation of Nrf2 and p53 defense mechanisms. *Redox Biol.* 2019, 24, 101206. [CrossRef]

114. Battino, M.; Giampieri, F.; Pistollato, F.; Sureda, A.; de Oliveira, M.R.; Pittalà, V.; Fallarino, F.; Nabavi, S.F.; Atanasov, A.G.; Nabavi, S.M. Nrfr2 as regulator of innate immunity: A molecular Swiss army knife! *Biotechnol. Adv.* 2018, 36, 355–360. [CrossRef] [PubMed]

115. Hirota, A.; Kawachi, Y.; Yamamoto, M.; Koga, T.; Hamada, K.; Otsuka, F. Acceleration of UVB-induced photoaging in Nrf2 gene-deficient mice. *Exp. Dermatol.* 2011, 20, 606–612. [CrossRef]

116. Vierkötter, A.; Schikowski, T.; Ranft, U.; Sugiri, D.; Matsui, M.; Krämer, U.; Krutmann, J. Airborne particle exposure and extrinsic skin aging. *Exp. Gerontol.* 2016, 74, 172–182. [CrossRef]

117. Quan, C.; Cho, M.K.; Perry, D.; Quan, T. Age-associated reduction of cell spreading induces mitochondrial DNA common deletion mutation in p53 gene-deficient mice. *Exp. Dermatol.* 2011, 20, 606–612. [CrossRef]

118. Singh, B.; Schoeb, T.R.; Bajpai, P.; Slominski, A.; Singh, K.K. Reversing wrinkled skin and hair loss in mice by restoring mitochondrial function. *Cell Death Dis.* 2018, 9, 735. [CrossRef]

119. Schäfer, M.; Werner, S. Nrfr2—A regulator of keratinocyte redox signaling. *Free Radic. Biol. Med.* 2015, 88, 243–252. [CrossRef]

120. Chaiprasongsuk, A.; Janietovic, Z.; Kim, T.K.; Jarrett, S.G.; D’Orazio, J.A.; Holick, M.F.; Tang, E.K.Y.; Tuckey, R.C.; Panich, U.; Li, W.; et al. Protective effects of vitamin D and gut microflora against UVB-induced damage in human keratinocytes involve activation of Nrf2 and p53 defense mechanisms. *Redox Biol.* 2019, 24, 101206. [CrossRef]

121. Battino, M.; Giampieri, F.; Pistollato, F.; Sureda, A.; de Oliveira, M.R.; Pittalà, V.; Fallarino, F.; Nabavi, S.F.; Atanasov, A.G.; Nabavi, S.M. Nrfr2 as regulator of innate immunity: A molecular Swiss army knife! *Biotechnol. Adv.* 2018, 36, 355–360. [CrossRef] [PubMed]

122. Hirota, A.; Kawachi, Y.; Yamamoto, M.; Koga, T.; Hamada, K.; Otsuka, F. Acceleration of UVB-induced photoaging in Nrf2 gene-deficient mice. *Exp. Dermatol.* 2011, 20, 606–612. [CrossRef]

123. Chaiprasongsuk, A.; Lohakul, J.; Soontrapsa, K.; Sampattavanich, S.; Akarakereenont, P.; Panich, U. Activation of Nrf2 Reduces UVA-Mediated MMP-1 Upregulation via MAPK/PAK 1 Signaling Cascades: The Photoprotective Effects of Sulforaphane and Hispidulin. *J. Pharmacol. Exp. Ther.* 2017, 360, 388–398. [CrossRef] [PubMed]

124. Rojo de la Vega, M.; Krajsnisk, A.; Zhang, D.D.; Wondrak, G.T. Targeting Nrf2 for Improved Skin Barrier Function and Photoprotection: Focus on the Achiote-Derived Apocarotenoid Bixin. *Nutrients* 2017, 9, 1371. [CrossRef] [PubMed]

125. Burke, K.E. Mechanisms of aging and development-A new understanding of environmental damage to the skin and prevention with topical antioxidants. *Mech. Ageing Dev.* 2018, 172, 123–130. [CrossRef] [PubMed]
128. Zhang, R.; Wang, Y.; Ye, K.; Picard, M.; Gu, Z. Independent impacts of aging on mitochondrial DNA quantity and quality in humans. BMC Genom. 2017, 18, 890. [CrossRef] [PubMed]

129. Bowman, A.; Birch-Machin, M.A. Age-Dependent Decrease of Mitochondrial Complex II Activity in Human Skin Fibroblasts. J. Investig. Dermatol. 2016, 136, 912–919. [CrossRef]

130. Bratic, A.; Larsson, N.G. The role of mitochondria in aging. J. Clin. Investig. 2013, 123, 951–957. [CrossRef] [PubMed]

131. Birch-Machin, M.A.; Russell, E.V.; Latimer, J.A. Mitochondrial DNA damage as a biomarker for ultraviolet radiation exposure and oxidative stress. Br. J. Dermatol. 2013, 169, 9–14. [CrossRef] [PubMed]

132. Naidoo, K.; Hanna, R.; Birch-Machin, M.A. What is the role of mitochondrial dysfunction in skin photoaging? Exp. Dermatol. 2018, 27, 124–128. [CrossRef]

133. Kennedy, C.; Badjik, C.D.; Willemze, R.; De Grujil, F.R.; Bouwes Bavinck, J.N. The influence of painful sunburns and lifetime of sun exposure on the risk of actinic keratoses, seborrheic warts, melanocytic nevi, atypical nevi and skin cancer. J. Investig. Dermatol. 2003, 120, 1087–1093. [CrossRef]

134. Skobowiat, C.; Dowdy, J.C.; Sayre, R.M.; Tuckey, R.C.; Slominski, A. Cutaneous hypothalamic-pituitary-adrenal axis homolog: Regulation by ultraviolet radiation. Am. J. Physiol. Endocrinol. Metab. 2011, 301, 484–493. [CrossRef]

135. Bickle, D.D. Vitamin D: An ancient hormone. Exp. Dermatol. 2011, 20, 7–13. [CrossRef]

136. Reichrath, J.; Saternus, R.; Vogt, T. Challenge and perspective: The relevance of ultraviolet (UV) radiation and the vitamin D endocrine system (VDES) for psoriasis and other inflammatory skin diseases. Photochem. Photobiol. Sci. 2017, 16, 433–444. [CrossRef]

137. Bikle, D.D. Vitamin D metabolism and function in the skin. Mol. Cell Endocrinol. 2011, 347, 80–99. [CrossRef]

138. Guryev, O.; Carvalho, R.A.; Usanov, S.; Gilep, A.; Estabrook, R.W. A pathway for the metabolism of vitamin D3: Unique hydroxylated metabolites formed during catalysis with cytochrome P450scc (CYP11A1). Proc. Natl. Acad. Sci. USA 2003, 100, 14754–14759. [CrossRef] [PubMed]

139. Slominski, A.; Semak, I.; Zjawiony, J.; Wortsman, J.; Li, W.; Szczesniewski, A.; Tuckey, R.C. The cytochrome P450scc system opens an alternate pathway of vitamin D3 metabolism. FEBS J. 2005, 272, 4080–4090.

140. Slominski, A.T.; Kim, T.K.; Hobrath, J.V.; Janjetovic, Z.; Oak, A.S.W.; Postlethwaite, A.; Lin, Z.; Kovacic, D.; Miller, D.D.; Postlethwaite, A.; et al. Novel products of vitamin D3 or 7-dehydrocholesterol metabolism by cytochrome P450scc show anti-leukemia effects, having low or absent calcemic activity. PLoS ONE 2010, 5, e9907. [CrossRef] [PubMed]

141. Slominski, A.T.; Janjetovic, Z.; Fuller, B.E.; Zmijewski, M.A.; Tuckey, R.C.; Nguyen, M.N.; Sweatman, T.; Li, W.; Zjawiony, J.; Miller, D.; et al. Products of vitamin D3 or 7-dehydrocholesterol metabolism by cytochrome P450scc show anti-leukaemia effects, having low or absent calcemic activity. PLoS ONE 2010, 5, e9907. [CrossRef] [PubMed]

142. Slominski, A.T.; Janjetovic, Z.; Kulkarni, A.; Chen, J.; Postlethwaite, A.E.; Miller, D.; Li, W. 20-hydroxyvitamin D3 inhibits proliferation of cancer cells with high efficacy while being non-toxic. Anticancer Res. 2012, 32, 739–746.

143. Slominski, A.T.; Kim, T.K.; Shehabi, H.Z.; Semak, I.; Tang, E.K.; Nguyen, M.N.; Benson, H.A.; Korik, E.; Janjetovic, Z.; Chen, J.; et al. In vivo evidence for a novel pathway of vitamin D3 metabolism initiated by P450scc and modified by CYP27B1. FASEB J. 2012, 26, 3901–3915. [CrossRef]

144. Slominski, A.T.; Kim, T.K.; Shehabi, H.Z.; Semak, I.; Tang, E.K.; Nguyen, M.N.; Benson, H.A.; Korik, E.; Janjetovic, Z.; Chen, J.; et al. In vivo evidence for a novel pathway of vitamin D3 metabolism initiated by P450scc and modified by CYP27B1. FASEB J. 2012, 26, 3901–3915. [CrossRef] [PubMed]

145. Slominski, A.T.; Kim, T.K.; Shehabi, H.Z.; Semak, I.; Tang, E.K.; Nguyen, M.N.; Benson, H.A.; Korik, E.; Janjetovic, Z.; Chen, J.; et al. In vivo evidence for a novel pathway of vitamin D3 metabolism initiated by P450scc and modified by CYP27B1. FASEB J. 2012, 26, 3901–3915. [CrossRef] [PubMed]

146. Slominski, A.T.; Kim, T.K.; Shehabi, H.Z.; Semak, I.; Tang, E.K.; Nguyen, M.N.; Benson, H.A.; Korik, E.; Janjetovic, Z.; Chen, J.; et al. In vivo evidence for a novel pathway of vitamin D3 metabolism initiated by P450scc and modified by CYP27B1. FASEB J. 2012, 26, 3901–3915. [CrossRef] [PubMed]
179. Slominski, A.T.; Janjetovic, Z.; Kim, T.K.; Wasilewski, P.; Rosas, S.; Hanna, S.; Sayre, R.M.; Dowdy, J.C.; Li, W.; Tuckey, R.C. Novel non-calcemic seco steroids that are produced by human epidermal keratinocytes protect against solar radiation. J. Steroid Biochem. Mol. Biol. 2015, 148, 52–63. [CrossRef]

180. Dixon, K.M.; Deo, S.S.; Norman, A.W.; Bishop, J.E.; Halliday, G.M.; Reeve, V.E.; Mason, R.S. In vivo relevance for photoprotection by the vitamin D rapid response pathway. J. Steroid Biochem. Mol. Biol. 2007, 103, 451–456. [CrossRef]

181. Gordon-Thomson, C.; Tongkao-on, W.; Song, E.J.; Carter, S.E.; Dixon, K.M.; Mason, R.S. Protection from ultraviolet damage and photocarcinogenesis by vitamin D compounds. Adv. Exp. Med. Biol. 2014, 810, 303–328. [PubMed]

182. Tongkao-On, W.; Carter, S.; Reeve, V.E.; Dixon, K.M.; Gordon-Thomson, C.; Halliday, G.M.; Tuckey, R.C.; Mason, R.S. CYP11A1 in skin: An alternative route to photoprotection by vitamin D compounds. J. Steroid Biochem. Mol. Biol. 2015, 148, 72–78. [CrossRef]

183. Song, E.J.; Gordon-Thomson, C.; Cole, L.; Stern, H.; Halliday, G.M.; Damian, D.L.; Reeve, V.E.; Mason, R.S. 1α,25-Dihydroxyvitamin D3 reduces several types of UV-DNA damage and contributes to photoprotection. J. Steroid Biochem. Mol. Biol. 2013, 136, 131–138. [CrossRef]

184. Chun, R.F.; Liu, P.T.; Modlin, R.L.; Adams, J.S.; Hewison, M. Impact of vitamin D on immune function: Lessons learned from vitamin D3 or dexamethasone: Differential role for PD-L1. Eur. J. Immunol. 2009, 39, 3147–3159. [CrossRef] [PubMed]

185. Veldman, C.M.; Cantorna, M.T.; DeLuca, H.F. Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system. Arch. Biochem. Biophys. 2000, 374, 334–338. [CrossRef] [PubMed]

186. Lipinska-Opalka, A.; Wawrzyniak, A.; Lewicki, S.; Zdanowski, R.; Kalicki, B. Evaluation of immune indices and serum vitamin D levels of women with psoriatic arthritis. J. Steroid Biochem. Mol. Biol. 2017, 170, 5382–5390. [CrossRef] [PubMed]

187. Amon, U.; Baier, L.; Yaguboglu, R.; Ennis, M.; Holick, M.F.; Amon, J. Serum 25-hydroxyvitamin D levels in patients with skin inflammatory disease or in healthy volunteers: A systematic review. PLoS ONE 2009, 4, e222313. [CrossRef] [PubMed]

188. Adorini, L.; Penna, G. Dendritic cell tolerogenicity: A key mechanism in immunomodulation by vitamin D receptor agonists. Hum. Immunol. 2009, 70, 345–352. [CrossRef]

189. Unger, W.W.; Laban, S.; Kleijwegt, F.S.; van der Slik, A.R.; Roep, B.O. Induction of Treg by monocyte-derived DC modulated by vitamin D3 or dexamethasone: Differential role for PD-L1. Eur. J. Immunol. 2009, 39, 3147–3159. [CrossRef] [PubMed]

190. Sassi, F.; Tamone, C.; D’Amelio, P. Vitamin D: Nutrient, Hormone, and Immunomodulator. Nutrients 2018, 10, 1656. [CrossRef]

191. Gorman, S.; Geldenhuys, S.; Weeden, C.E.; Grimbaldeston, M.A.; Hart, P.H. Investigating the roles of regulatory T cells, mast cells and interleukin-9 in the control of skin inflammation by vitamin D. Arch. Dermatol. Res. 2018, 310, 211–230. [CrossRef] [PubMed]

192. Lemire, J.M.; Archer, D.C.; Beck, L.; Spiegelberg, H.L. Immunosuppressive actions of 1,25-dihydroxyvitamin D levels in patients with skin diseases including psoriasis, infections, and atopic dermatitis. Dermatoendocrinology 2018, 10, e1442159. [CrossRef]

193. Veldman, C.M.; Cantorna, M.T.; DeLuca, H.F. Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system. Arch. Biochem. Biophys. 2000, 374, 334–338. [CrossRef] [PubMed]

194. Yip, K.H.; Kolesnikoff, N.; Yu, C.; Hauschild, N.; Taing, H.; Biggs, L.; Goltzman, D.; Gregory, P.A.; Anderson, P.H.; Samuel, M.S.; et al. Mechanisms of vitamin D metabolism and interleukin-9 in the control of skin inflammation by vitamin D. Arch. Dermatol. Res. 2010, 302, 1634–1647. [CrossRef]

195. Yip, K.H.; Kolesnikoff, N.; Yu, C.; Hauschild, N.; Taing, H.; Biggs, L.; Goltzman, D.; Gregory, P.A.; Anderson, P.H.; Samuel, M.S.; et al. Mechanisms of vitamin D metabolism and interleukin-9 in the control of skin inflammation by vitamin D. Arch. Dermatol. Res. 2010, 302, 1634–1647. [CrossRef]

196. Wang, T.T.; Nestel, F.P.; Bourdeau, V.; Nagai, Y.; Wang, Q.; Liao, J.; Tavaera-Mendoza, L.; Lin, R.; Hanrahan, J.W.; Mader, S.; et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J. Immunol. 2004, 173, 2909–2912. [CrossRef] [PubMed]

197. Heine, G.; Niesner, U.; Chang, H.D.; Steinmeyer, A.; Zügel, U.; Zuberbier, T.; Radbruch, A.; Worm, M. 1,25-dihydroxyvitamin D(3) promotes IL-10 production in human B cells. J. Immunol. 2008, 180, 2210–2218. [CrossRef]

198. Wang, T.T.; Nestel, F.P.; Bourdeau, V.; Nagai, Y.; Wang, Q.; Liao, J.; Tavaera-Mendoza, L.; Lin, R.; Hanrahan, J.W.; Mader, S.; et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J. Immunol. 2004, 173, 2909–2912. [CrossRef] [PubMed]

199. Svensson, D.; Nebel, D.; Nilsson, B.O. Vitamin D3 modulates the innate immune response through regulation of the hCAP-18/LL-37 gene expression and cytokine production. Inflamm. Res. 2016, 65, 25–32. [CrossRef] [PubMed]
233. Mouret, S.; Baudouin, C.; Charveron, M.; Favier, A.; Cadet, J.; Douki, T. Cyclobutane pyrimidine dimers are predominant DNA lesions in whole human skin exposed to UVA radiation. *Proc. Natl. Acad. Sci. USA* **2006**, *103*, 13765–13770. [CrossRef] [PubMed]

234. Gupta, R.; Dixon, K.M.; Deo, S.S.; Holliday, C.J.; Slater, M.; Halliday, G.M.; Reeve, V.E.; Mason, R.S. Photoprotection by 1,25 dihydroxyvitamin D3 is associated with an increase in p53 and a decrease in nitric oxide products. *J. Investig. Dermatol.* **2007**, *127*, 707–715. [CrossRef]

235. Dixon, K.M.; Sequeira, V.B.; Deo, S.S.; Mohan, R.; Posner, G.H.; Mason, R.S. Differential photoprotective effects of 1,25-dihydroxyvitamin D3 and a low calcemic deltanoid. *Photochem. Photobiol. Sci.* **2012**, *11*, 1825–1830. [CrossRef] [PubMed]

236. Paris, M.; Rouleau, M.; Pucaüt, M.; Aberdam, D. Regulation of skin aging and heart development by TAp63. *Cell Death Differ.* **2012**, *19*, 186–193. [CrossRef] [PubMed]

237. Kudryavtseva, A.V.; Krasnov, G.S.; Dmitriev, A.A.; Alekseev, B.Y.; Kardymon, O.L.; Sadritdinova, A.F.; Fedorova, M.S.; Pokrovsky, A.V.; Melnikova, N.V.; Kaprin, A.D.; et al. Mitochondrial dysfunction and oxidative stress in aging and cancer. *Oncotarget* **2016**, *7*, 44879–44905. [CrossRef] [PubMed]

238. Mason, R.S.; Sequeira, V.B.; Dixon, K.M.; Gordon-Thomson, C.; Pobre, K.; Dilley, A.; Mizwicki, M.T.; Norman, A.W.; Feldman, D.; Halliday, G.M.; et al. Photoprotection by 1alpha,25-dihydroxyvitamin D and analogs: Further studies on mechanisms and implications for UV-damage. *J. Steroid Biochem. Mol. Biol.* **2010**, *121*, 164–168. [CrossRef] [PubMed]

239. Sequeira, V.B.; Rybchyn, M.S.; Gordon-Thomson, C.; Tongkao-On, W.; Mizwicki, M.T.; Norman, A.W.; Reeve, V.E.; Halliday, G.M.; Mason, R.S. Opening of chloride channels by 1alpha,25-dihydroxyvitamin D3 contributes to photoprotection against UVR-induced thymine dimers in keratinocytes. *J. Investig. Dermatol.* **2013**, *133*, 776–782. [CrossRef]

240. Janjetovic, Z.; Tuckey, R.C.; Nguyen, M.N.; Thorpe, E.M., Jr.; Slominski, A.T. 20,23-dihydroxyvitamin D3, novel P450scc product, stimulates differentiation and inhibits proliferation and NF-kappaB activity in human keratinocytes. *J. Cell Physiol.* **2010**, *223*, 36–48.

241. Janjetovic, Z.; Zmijewski, M.A.; Tuckey, R.C.; DeLeon, D.A.; Nguyen, M.N.; Pfeffer, L.M.; Slominski, A.T. 20-Hydroxycholecalciferol, product of vitamin D3 hydroxylation by P450scc, decreases NF-kappaB activity by increasing IkappaB alpha levels in human keratinocytes. *PloS ONE* **2009**, *4*, e5988. [CrossRef]

242. Wong, G.; Gupta, R.; Dixon, K.M.; Deo, S.S.; Choong, S.M.; Halliday, G.M.; Bishop, J.E.; Ishizuka, S.; Norman, A.W.; Posner, G.H.; et al. 1,25-Dihydroxyvitamin D and three low-calcemic analogs decrease UV-induced DNA damage via the rapid response pathway. *J. Steroid Biochem. Mol. Biol.* **2004**, *89–90*, 567–570. [CrossRef] [PubMed]

243. Slominski, R.M.; Stefan, J.; Athar, M.; Hollick, M.F.; Jetten, A.M.; Raman, C.; Slominski, A.T. COVID-19 and Vitamin D: A lesson from the skin. *Exp. Dermatol.* **2020**, *29*, 885–890. [CrossRef] [PubMed]